RPCEC00000008已完成2 期
Active specific immunotherapy with 1E10 anti-idiotype vaccine to treat patients with metastatic breast cancer, phase II.
Center of Molecular Immunology (CIM)0 个研究点目标入组 80 人开始时间: 2010年12月27日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled trial. Masking: Double Blind. Control group: Active. Assignment: Parallel. Purpose: Treatment
入排标准
- 年龄范围
- 18 years 至 80 years（—）
- 性别
- Female
入选标准
- •1)Female patients with cyto- ’histological confirmed diagnostic of recurrent or Stage IV metastatic breast cancer 2)Patients that have received the oncospecific therapy according to the treatment guidelines established in the country and that have ended the different protocols in a time period of 4 weeks prior to entry in the trial. 3)Patient’s informed consent to participate in the investigation obtained. 4)Age = 18 years. 5)Patients with life expectancy = 6 months. 6)Performance Status according to WHO from 0 to 2. 7)Clinical laboratory parameters: a.-) Hematopoietic parameters: - Hb>100g/l, - Leucocytes>4 x 109cells/l - Granulocytes>2x109 cells/l, - Platelets> 100 x 109cells/ l. b.-) Liver (not exceeding the normal upper limit by three times), bilirubin: 17mol/l (LSN), ALAT: 40U/l (LSN), ASAT: 40U/l (LSN), alkaline phosphatase: 279U/l c.-) Kidney: serum creatinine: 132 mmol/l.
排除标准
- •1.Patients with breast cancer in stage Iv or recurrent diseases that have received oncospecific therapy and have concluded the different protocols in a time period inferior to 4 weeks or greater than 4 weeks prior to entry in the trial. 2.Pregnant or breastfeeding patients. 3.Patients with prior history of demielinizing disease or inflammatory disease of the CNS or the peripheral nervous system. 4.Patients with previous malignancies except carcinoma in situ of cervix or skin cancer (not melanoma), treated properly. 5.Patients with acute or chronic infectious diseases. 6.Patients with acute allergic status or history of severe allergic reactions. 7.Patients with autoimmune diseases or chronic non-compensated diseases. 8.Patients who present the contralateral breast as the only site of metastatic disease.
研究者
相似试验
已完成
2 期
1E10 anti-idiotype vaccine, metastatic colon, phase II.Colon adenocarcinoma phase IV or evolvable metastatic diseaseColonic NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsColonic DiseasesIntestinal DiseasesGastrointestinal DiseasesDigestive System DiseasesColorectal NeoplasmsRPCEC00000006Center of Molecular Immunology (CIM)40
已完成
2 期
Anti-idiotype 1E10 vaccine in the treatment of patients with small cell lung (SCLC) patientsAdvanced Lung Cancer Small Cell Lung CancerSmall Cell Lung CarcinomaCarcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsLung DiseasesRespiratory Tract DiseasesRPCEC00000010Center of Molecular Immunology (CIM)88
招募中
1 期
GcGM3/VSSP in small cell lung cancerCarcinoma, BronchogenicRespiratory Tract NeoplasmsLung NeoplasmsSmall cell lung cancerBronchial NeoplasmsSmall Cell Lung CarcinomaThoracic NeoplasmsLung DiseasesRespiratory Tract DiseasesRPCEC00000224Center of Molecular Immunology (CIM)40
招募中
2 期
GcGM3/VSSP in Metastatic melanomaMetastatic melanomaNevi and MelanomasNeuroendocrine TumorsNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms, Nerve TissueMelanomaRPCEC00000223Center of Molecular Immunology (CIM)160
尚未招募
2 期
GcGM3/VSSP in patients with metastatic hormone-receptor positive and HER2 negative breast cancerMetastatic hormone-receptor positive and HER2 negative breast cancerBreast NeoplasmsBreast DiseasesRPCEC00000220Center of Molecular Immunology (CIM)286